Magnetic Ventures

Congratulations to Magnetic Ventures portfolio company Weave Bio on its Series A financing, led by USVP. Magnetic co-led the Seed financing with Innovation Endeavors. We bet on Weave because we recognized certain processes in biotech and pharma were ripe to be radically improved with technology, and regulatory was at the top of the list. The regulatory filing process takes far too long and is too manual. If we could speed the process of getting a drug candidate into patients for testing (IND), we could help accelerate getting drugs to market sooner. Fast forward - Weave has built a fundamentally sound business with proven customer traction and revenue. They have built an essential AI infrastructure for regulatory workflows - a universal, high-impact bottleneck that affects every drug, every company and every therapeutic category and connects the dots across the entire therapeutic lifecycle. From the first preclinical submission to post-market updates years later, everything lives in one AI-native system. That's the difference between point solutions and platform value. Since our initial Seed financing in December 2024, Weave has been able to deploy this AI-native system and secure top pharma, biotech and CROs as customers. This is AI AT WORK. This is AI making a meaningful difference to help pharma and biotech deliver new therapeutics to patients sooner. And, this is why I founded Magnetic - to identify (early) and support (throughout the lifecycle) founders who use technology to solve problems and improve patient's lives. Congratulations to the entire team, including Weave Co-founder and Magnetic Venture Partner Umut Eser, Co-founder and CEO Brandon Rice, Co-founder Ari Caroline. Read More: https://lnkd.in/eGST_Q_w

Congratulations to Kent Thoelke 🏳️🌈 and the Paradigm Health team on this important partnership with Parexel! #clinicaltrials #healthequity #AI #healthcaretech

Congratulations to Magnetic Ventures portfolio company Paradigm Health on its strategic partnership with Parexel to expand access and efficiency in clinical trials. By combining Paradigm’s AI-enabled trial platform with Parexel’s world-class global infrastructure, the collaboration will redefine how trials are designed and delivered. For sponsors, this means faster, more representative, and cost-efficient trials. For patients, it means clinical research integrated into routine care and earlier access to life-changing therapies. The Magnetic team is proud to support the Paradigm Health team on their mission to create a more equitable and efficient clinical trial ecosystem. Congratulations Kent Thoelke, Paradigm Health, and Parexel. Read More: https://lnkd.in/eRj-z33d #ClinicalTrials #AIinHealthcare #Biopharma #Patients #Cause2Cure #ParadigmHealth #Parexel

Collaboration is a catalyst for innovation, especially in healthtech and life sciences. Congratulations to Magnetic Ventures portfolio company Relation Therapeutics for being featured in Forbes highlighting how London biotechs are leveraging partnerships to accelerate their path to market. The article highlights a key insight from Relation Therapeutics CEO David Roblin: "Trying to innovate in a big company with established processes is quite a challenge. GSK had all the elements but they didn’t have the blank sheet of paper to bring the technologies to bear at the right time and at the right pace." Relation’s collaboration with GSK on treatments for osteoarthritis and fibrosis is a perfect example of this synergy: 🔹For Big Pharma: Access to agile innovation and fresh interdisciplinary approaches 🔹For Startups: Enhanced credibility, validation, and resources to accelerate timelines. Located in London’s Knowledge Quarter, Relation is part of a thriving ecosystem where proximity to world-class research institutions, hospitals, and tech leaders fuels cross-pollination and breakthroughs. We’re proud to continue to support Relation as they redefine drug discovery through cutting-edge technology and biology. 📖 Read the full Forbes article: https://lnkd.in/dz7f7inv #TechBio #AI #Biotech #DrugDiscovery #Innovation #HealthTech #Cause2Cure #Partnerships

🎙️ Great conversation with Relation Therapeutics CEO David Roblin and Luke Timmerman on Luke’s The Long Run podcast. David shares the story behind Relation—from his own journey as a physician and R&D executive to building a company focused on improving the fundamentals of drug discovery. 💡 Highlights from the episode include: 🔹Why better biology is key to reducing phase II failure 🔹The role of human tissue and real-world data in driving discovery 🔹Building Relation’s unique platform and culture from the ground up 🔹New programs in osteoporosis, fibrosis, and osteoarthritis—including a recent partnership with GSK Magnetic Ventures is proud to support Relation on this journey and to partner with a team redefining the future of drug discovery. 🎧 Listen to the episode: https://lnkd.in/ewv5HTWD #TechBio #AI #Biotech #DrugDiscovery #Innovation #HealthTech #Cause2Cure

Welcome Dr. Sara-Jane Dunn (“SJ”) to the Magnetic Ventures network as she joins Relation Therapeutics as Vice President of Computational Research. SJ brings a rare combination of deep technical expertise and scientific vision—joining Relation from Google DeepMind, where she helped shape the application of deep learning to biology. Her research spans foundational work in computational modeling and systems biology, with publications in Science, Neuron, and eLife, and a widely viewed TED talk on programming biological cells. https://lnkd.in/daQuWEp At Relation, she will help drive platform development at the intersection of machine learning and single-cell omics—advancing the company’s mission to identify high-conviction drug targets rooted in human biology. 🌍 Headquartered in London’s Knowledge Quarter, Relation brings together a deeply interdisciplinary team of scientists, engineers, and drug developers—united by a clear mission: to advance high-quality medicines for patients who are still waiting. SJ is a wonderful addition! We’re proud to support Relation as it continues to scale its team and platform to tackle some of the most pressing challenges in drug discovery. #TechBio #Biotech #AI #DrugDiscovery #HealthTech #Innovation

We’re thrilled to be featured in the BioIndustry Association (BIA) report on UK biotech financing and also highlighted in the DCVC 2024 report. This recognition celebrates what has been an extraordinary year for Relation in 2024. 📈 Key milestones: 🔒 Successfully closing our seed round with the incredible support of our lead investors DCVC, Magnetic Ventures, NVIDIA NVentures, and more. 🙌 🤝 Entering an exciting partnership with GSK, marking a pivotal moment in our mission to harness cutting-edge technology and biology to discover transformational medicines. 🧬🤖 These achievements showcase how Relation is driving innovation at the intersection of machine learning, multi-omics, and functional biology. We're grateful to our investors, partners, and incredible team for making it all possible. 👉 Explore the highlights: >> DCVC report: TechBio and data-centric AI in 2024 https://lnkd.in/gxk26CkR >> BIA UK Biotech Financing 2024 report: https://lnkd.in/dugDc43E The patient is waiting. #cause2cure #code2cure #techbio #innovation #drugdiscovery David Roblin

Congratulations to Magnetic Ventures portfolio company Terrain Biosciences for emerging from stealth with $9M in Seed financing and a mission to revolutionize RNA therapeutics and vaccine development. Terrain is pioneering the world’s first RNA design-build platform that leverages advanced AI and a proprietary manufacturing process to optimize and deliver high quality mRNA sequences, 3-6x faster than industry standards. Founded by Omar Abudayyeh, Jonathan Gootenberg of The Abu Goot Lab at Harvard University,  Patrick Hsu Hsu Co founder of Arc Institute & Assistant Professor of Bioengineering at University of California, Berkeley, and led by CEO Chetan Tadvalkar. Magnetic is thrilled to partner with this incredible team and additional investors including Bruker Corporation, Josef Feldman, and biotech leaders John Maraganore, Hans Bishop, and John Evans, among others. Overcoming challenges in RNA sequence optimization, will pave the way for breakthroughs in oncology, infectious diseases, neurodegenerative illnesses, and more, and we look forward to supporting Terrain as they continue to grow.  Learn more about Terrain’s journey and connect with their design and build team at terrainbiosciences.com. #AI #Biotech #Innovation #HealthTech #RNA #Therapeutics #VaccineDevelopment #DeepTech #StartupLaunch Read more in detail here: https://lnkd.in/dTediD6k

As we reflect on the technical advances that enable our portfolio companies to make key discoveries in 2024, we are sharing an excellent overview of the rapidly evolving landscape of single-cell and spatial omics technologies in the context of drug development by Jake P. Taylor-King and colleagues at Relation. The team evaluates next-generation sequencing and image-based spatial transcriptomics approaches and highlights the emerging technical advances that can expand the scope of data generation to discover and validate novel drug mechanisms. #omics #nextgensequencing #data #techbio https://lnkd.in/dxFVtqF3